represented and suggested that the article would be effective in the treatment of disturbances of the mammary system of dairy cattle; that it would be effective to build up resistance of the animals to prevent any disturbance of the mammary system; and that the Flex-O Udder Ointment would be effective to assist the healthy milk secretion and flow of blood to the udder.

Flex-O Udder Ointment. Misbranding, Section 502 (a), certain label statements were false and misleading since they represented and suggested that the article would be effective in the treatment of disease conditions of the udder

Flex-O Scourene. Misbranding, Section 502 (a), the designation "Scourene" and certain label statements were false and misleading since they represented and suggested that the article would be effective for the disease condition of animals known as scours; that it would be effective as an astringent medication for intestinal derangements of farm and dairy animals; that it would be effective for intestinal infections in farm animals; that it would be effective as an astringent; and that it would be effective in the treatment of simple scours in calves, colts, pigs, dogs, and lambs, or where such contagion exists among fowls.

The articles would not be effective for the purposes claimed.

Disposition: January 21, 1947. No claimant having appeared, judgment of forfeiture was entered and the product was ordered destroyed.

DRUGS ACTIONABLE BECAUSE OF OMISSION OF, OR UNSATISFACTORY, INGREDIENTS STATEMENTS*

1999. Misbranding of estrogenic substance powder and estrogenic substance in sesame oil. U. S. v. 1 Bottle of Estrogenic Substance Powder (and 2 seizure actions against Estrogenic Substance in Sesame Oil). Consent decrees of condemnation. Products ordered released under bond to be relabeled. (F. D. C. Nos. 16265, 16288, 16289. Sample Nos. 3846-H, 3847-H, 4085-H, 31328-H.)

Libels Filed: Between May 23 and 31, 1945, Southern District of California and Eastern District of Pennsylvania.

ALLEGED SHIPMENT: On or about March 27 and April 10, 1945, by the Hormorgano Corporation, from Jamaica, N. Y.

PRODUCT: 1 bottle of estrogenic substance powder at Pasadena, Calif., and 10 bottles of estrogenic substance in sesame oil at Philadelphia. Pa. Examination showed that the estrogenic substance powder contained 20 percent of estrogenic or other phenolic compounds and 80 percent of a diluent. The estrogenic potency was due principally to estradiol. Examination of the estrogenic substance in sesame oil showed that the product was an oil solution containing principally estradiol, with perhaps a small proportion of estrone or other ketosteroids.

LABEL, IN PART: "Estrogenic Substance in Sesame Oil," or "Estrogenic Substance Powder."

NATURE OF CHARGE: Misbranding, Section 502 (e), the products were fabricated from two or more ingredients and the labels failed to bear the common or usual name of each active ingredient, since the label designation "Estrogenic Substance" is not the specific name of any particular substance, but is a generic name for a class of substances.

Disposition: June 19 and September 7, 1945. The Hormorgano Corporation, claimant, having consented to the entry of decrees, and the Philadelphia cases having been consolidated, judgments of condemnation were entered and the products were ordered released under bond to be relabeled under the supervision of the Food and Drug Administration.

2000. Misbranding of estrogenic substance. U. S. v. 1 Bottle of Estrogenic Substance. Consent decree of condemnation. Product ordered released under bond. (F. D. C. No. 19581. Sample No. 45051-H.)

LIBEL FILED: April 1, 1946, Southern District of California.

ALLEGED SHIPMENT: On or about March 1, 1946, by the Tremond Co., from Brooklyn, N. Y.

PRODUCT: 1 bottle of estrogenic substance at Los Angeles, Calif.

NATURE OF CHARGE: Misbranding, Section 502 (e) (2), the article was fabricated from two or more ingredients and its label failed to bear the common or

^{*}See also Nos. 1955, 1956, 1961, 1962, 1966, 1978, 1997.


usual name of each active ingredient, since the label designation "Estrogenic Substance" is not the specific name of any particular substance, but is a generic name for a class of substances.

DISPOSITION: July 16, 1946. The Tremond Co., New York, N. Y., claimant, having consented to the entry of a decree, judgment of condemnation was entered and the product was ordered released under bond for relabeling under the supervision of the Federal Security Agency.

INDEX TO NOTICES OF JUDGMENT D. D. N. J. NOS. 1951 TO 2000 PRODUCTS

N. J. No. Medicrude 1993 Mineral Water 1989 Ointments 1953, 1957,1966 Abortifacient 1956 Ademo Tablets_____ 1985 Allen's Nijara Capsules_____ 1982 Amphetamine sulfate tablets____ 1954 Paddock's, Dr., Medicines____ 2 1980 Paralax 1997 Parenteral drugs 1951, 1954, 1967-Applicators, cotton-tipped_____ 1984 Atabrine tablets_____ 1954 1970, 1972–1975, 1999, 2000 B-Parplex______ 1975 Belladonna_____ 1965 Pratts Poultry Worm Powder Chinaroid Rectal Balm_____ 1957 and Pratts N-K Capsules____ 1996 Clover Dairy Ointment_____ 1966 Prophylactics _____ 1979 Cosmetic (subject to the drug Pyo-Gon Iodophenols_____ 1977 provisions of the Act)_____ 1978 Rayo Balm______ 1988 Reiner's Rinol_____ 1992 D-X Tablets_____ 1991 Dental cartridges_____ 1962 Salt solutions, physiological____ 1973 Devices_____ 1979, 1984, 1986 Sano _____ 1983 Sea Vegecene (Powder) and Sea-Devonshire's Earth Salts_____ 1990 Diarex _____ 1997 Vo-Kra Tablets_____ 1991 Estrogenic substances_____ 1968-1970, Sills Foot Treatment Combina-1999, 2000 tion Package, Powder Foot Treatment, Powder Treatment, and Ingrown Nail Relief Estrovin in oil_____ 1968, 1969 FYA Tablets______ 1991 Ferrolene Tablets_____ 1991 1987 First aid kits_____ Sleepy Valley Mineral Water____ 1954 1989 Special Compressed Tablets____ Flex-O Scourene and Flex-O Ud-1964 der Ointment_____ 1998 Stramonium _____ 1965 1995 Sulfadiazine tablets_____ 1954 Glando-Plex Tablets_____ Sulfanilamide, crystalline_____ 1961 1952 Imported Sea Vegetable Tablets Sulfasol _____ 1994 and Imported Sea Vegeta-Swinade _____ 1997 tion Tablets_____ Testocrin in Oil 1991 1969 Theobromine-Ioform with Phe-Improved Special Tablets_____ 1958 nobarbital _____ Todd's Tonic Bitters, Laxano-Injection preparations. See Pa-1976 renteral drugs. dine, and Irontone_____ Interferin _____ 1956 1955 Tooth powder_____ Intrauterine paste_____ 1956 1978 Kalseom _____ 1991 Trexcene Special Tablet Compound _____ Knox-It 1998 1960 Kohl's All Soothing Ointment__ Veterinary preparations_____ 1953 Laxatives without required 1966, 1993-1998 warning statements____ 1955, 1960 Vitamin preparations__ 1982, 1985, 1991 Lax-A-Ton _____ 1997 Vitaminized Imported Sea Vege-Livo-Plex _____ 1951 tation Tablets and Vitamin-Magnesium citrate, solution of 1971 Mag-Net-O-Balm 1981 ized Sodeom Tablets_____ 1991 Vrilium Catalytic Barium Chlo-Mar-Glo Tablets_____ 1991 ride _____ 1986 Martin's Sulfa-Rea Powder, Phe-W-Whey **19**59 nika Wormer, and Pheno-Water for injection____ 1967, 1972, 1974 thiazine Powder_____ 1963 | West-Aid Tablets_____ 1991

^{1 (1981)} Permanent injunction issued.
2 (1980) Permanent injunction issued. Contains opinions of the court, findings of fact, and conclusions of law.



FEDERAL SECURITY AGENCY

FOOD AND DRUG ADMINISTRATION

NOTICES OF JUDGMENT UNDER THE FEDERAL FOOD, DRUG, AND COSMETIC ACT

[Given pursuant to section 705 of the Food, Drug, and Cosmetic Act]

2001-2050

DRUGS AND DEVICES

The cases reported herewith were instituted in the United States district courts by the United States attorneys acting upon reports submitted by direction of the Federal Security Administrator.

MAURICE COLLINS, Acting Administrator, Federal Security Agency. Washington, D. C., June 5, 1947.

CONTENTS*

	Page	1	Page
Drug actionable because of potential danger when used according to directions	281	Drugs and devices actionable because of devi- ation from official or own standards	289
Drug requiring certificate or release, for which none had been issued	282	Drugs and devices actionable because of false and misleading claims	294
Drugs actionable because of failure to bear adequate directions or warning statements	282	Drugs for human use Drugs for veterinary use	294 301
Drugs actionable because of contamination with filth	287	Drugs actionable because of failure to bear ac- curate statements of the quantity of the	
Drug actionable because of the presence of a noncertified coal-tar color	288	contents Index	305 306

DRUG ACTIONABLE BECAUSE OF POTENTIAL DANGER WHEN USED ACCORDING TO DIRECTIONS

2001. Misbranding of Anademin Tablets. U. S. v. 52 Packages and 5 Packages of Anademin Tablets. Default decree of condemnation and destruction. (F. D. C. No. 20102. Sample No. 14079–H.)

LIBER FILED: June 26, 1946, Southern District of Ohio.

ALLEGED SHIPMENT: On or about October 30, 1945, and April 8 and May 29, 1946, by the Anademin Chemical Co., from Chattanooga, Tenn.

PRODUCT: 52 100-tablet packages and 5 500-tablet packages of Anademin Tablets at Cincinnati, Ohio. Assay by the method described in the Twelfth Revision of the United States Pharmacopoeia showed that each tablet of the product had a potency of 3.17 U. S. P. Digitalis Units.

LABEL, IN PART: "100 [or "500"] 5 grain Tablets Anademin * * * * Caution: To be used only by or on the prescription of a physician. Assay: As assayed by the method described in U. S. P. XII for Digitalis, each tablet has a potency of 1.25 U. S. P. Digitalis units."

^{*}For omission of, or unsatisfactory, ingredients statements, see Nos. 2003, 2005, 2008, 2031, 2034, 2035, 2046; failure to comply with the packaging requirements of an official compendium. No. 2028; failure to bear a label containing the name and place of business of the manufacturer, packer, or distributor, Nos. 2003, 2028.